Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
44 hedge funds and large institutions have $1.2M invested in Syros Pharmaceuticals, Inc. Common Stock in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 29 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
32% less funds holding
Funds holding: 65 → 44 (-21)
72% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 29
85% less call options, than puts
Call options by funds: $55K | Put options by funds: $355K
97% less capital invested
Capital invested by funds: $40.8M → $1.2M (-$39.6M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$236K |
| 2 |
AAA
Affinity Asset Advisors
New York
|
+$180K |
| 3 |
Citigroup
New York
|
+$166K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$129K |
| 5 |
HF
HRT Financial
New York
|
+$105K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$5.56M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.45M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$3.84M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.16M |
| 5 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$2.78M |
SYRS Hedge Fund Activity: Q4 2024 in Review
44 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q4 2024, worth a combined $1.2M — down 97% from $40.8M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of SYRS and 8 opened new positions — a net loss of 21 holders — while 7 trimmed existing stakes and 10 added.
The largest buyer was Acadian Asset Management, adding an estimated $236K. The largest seller was Siren LLC, exiting entirely with an estimated $5.56M sold.
- 44 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q4 2024, down from 65 in Q3 2024.
- Funds reported $1.2M of Syros Pharmaceuticals, Inc. Common Stock stock for Q4 2024, down 97% quarter-over-quarter.
- 8 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q4 2024 and 29 closed out, a net change of -21 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q4 2024 was Acadian Asset Management, an estimated $236K added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q4 2024 was Siren LLC, an estimated $5.56M sold.
Based on aggregated 13F filings for Q4 2024.